Morgan Stanley updates Asymchem Laboratories' risk-reward; target price Rmb140, rating Equal-weight

Overview

This report is Morgan Stanley's risk-reward update on Asymchem Laboratories. Inc (002821.SZ). Based on 2025 results, the report raised 2026-30 earnings forecasts by 2-4%, mainly reflecting higher revenue assumptions; target price and scenario values were also raised by 1-5%. The company is described as one of China's leading small-molecule CDMOs and has potential to expand global revenue exposure.

Core views

The core view is that the company holds a leading position in China's small-molecule CDMO market, and if large orders from multinational pharma companies, GLP-1 orders, and new modality businesses scale up, earnings resilience and operating leverage could be strong. However, due to slowing industry growth, limited short-term order visibility, and macro uncertainty in emerging businesses, Morgan Stanley keeps an Equal-weight view.

Analysis framework

The report assesses investment returns through a risk-reward framework and scenario valuation: the bull case assumes rapid GLP-1 order ramp-up and earnings CAGR above 30% during 2025-28; the base case assumes 2025-28 revenue CAGR of 18%, stable gross margin, and improving capacity utilization; the bear case assumes weak demand, slower-than-expected recovery in revenue and margins, and earnings CAGR below 5% during 2025-28.

Methodology notes

• Valuation methodDCF

  Discounted cash flow valuation

  The target price comes from a DCF model, with key assumptions including a 10.5% WACC, a 3.0% terminal growth rate, and an RMB/HKD exchange rate of 1.1.

• Risk-rewardMorgan Stanley Risk Reward

  Bull, base, and bear scenarios

  The report builds scenario values of Rmb330, Rmb140, and Rmb100 using different assumptions for order growth, gross margin, capacity utilization, and demand.

• Research modelMorgan Stanley ModelWare

  Model-based financial forecasts

  The report states that, unless otherwise noted, metrics are based on the Morgan Stanley ModelWare framework.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Asymchem Laboratories. Inc (002821.SZ)

  Research coverage

  Strengths

  One of China's leading small-molecule CDMOs, with the potential to gain market share, expand global revenue exposure, and scale large orders from multinational pharma companies and GLP-1 orders.

  Weaknesses

  Industry growth is slowing, short-term order visibility is limited, and emerging businesses remain exposed to macro uncertainty.

  Comparison

  Relative to the sector coverage universe, Equal-weight indicates that its expected risk-adjusted total return is broadly in line with the sector average.

  Risks

  Weak demand, low capacity utilization, changes in project mix, pricing pressure, intensifying competition, geopolitical risk, and FX risk.

Key data

• RatingEqual-weightUnder Morgan Stanley's relative rating system, Equal-weight means the expected risk-adjusted total return over the next 12-18 months is broadly in line with the average of the covered sector.
• Target priceRmb140.00The report says the target price and scenario values were raised 1-5%.
• Bull-case scenario valueRmb330.00Assumes rapid GLP-1 order ramp-up and earnings CAGR above 30% during 2025-28.
• Base-case scenario valueRmb140.00Assumes 2025-28 revenue CAGR of 18%, stable gross margin, and improved capacity utilization.
• Bear-case scenario valueRmb100.00Assumes weak demand, revenue and margins below the base case, and earnings CAGR below 5% during 2025-28.
• Earnings forecast revisionUp 2-4% for 2026-30The increase reflects higher revenue assumptions.
• DCF assumptionsWACC 10.5%; terminal growth rate 3.0%The report also uses an RMB/HKD exchange rate of 1.1.

Impact & implications

For investors, the implication is that Asymchem's medium-term upside depends mainly on whether overseas large orders, GLP-1 orders, new modality orders, and improved capacity utilization can materialize. If orders ramp faster than expected, there is significant upside in valuation; but if demand, pricing, project mix, or competition worsen, margins and earnings recovery could come under pressure.

Risks

• Industry growth or demand for small-molecule drugs could be weaker than expected.
• Service backlog and customer orders could come in below expectations.
• Without large post-pandemic orders, capacity utilization and margins may be weaker than expected.
• Changes in project mix, excess capacity, rising competition, and business expansion could erode margins.
• Deterioration in the domestic competitive landscape.
• Geopolitical and FX risks.
• Contribution from emerging businesses could fall short of expectations.

What to watch

• Whether overseas large orders continue, especially multinational pharma orders amid easing China-U.S. tensions.
• The pace of GLP-1-related order ramp-up.
• Changes in capacity utilization at the small-molecule CDMO and large-molecule chemistry CDMO businesses.
• Revenue contribution from new modality orders and emerging businesses.
• Whether an improved financing environment supports resilient small-molecule order demand.
• Gross margin, pricing, and project mix changes.